CP-x Synthetic Cannabinoids Cannabinoid Research

CP-x Synthetic Cannabinoids Research Dashboard

30

Primary Studies

39

Related Studies

69

Total Studies

Clinical Studies

0

Clinical Meta-analyses

2

Double-blind human trials

1

Clinical human trials

Pre-Clinical Studies

1

Meta-analyses/Reviews

12

Animal studies

13

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 69 studies associated with CP-x Synthetic Cannabinoids.

Here is a small sampling of CP-x Synthetic Cannabinoids studies by title:


Components of the CP-x Synthetic Cannabinoids Research Dashboard

  • Top medical conditions associated with CP-x Synthetic Cannabinoids
  • Proven effects in clinical trials for CP-x Synthetic Cannabinoids
  • Receptors associated with CP-x Synthetic Cannabinoids
  • Individual study details for CP-x Synthetic Cannabinoids

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - CP-x Synthetic Cannabinoids

Description of CP-x Synthetic Cannabinoids

The CP- class of synthetic cannabinoids are named after the company Carl Pfizer where they were first synthesized.

CP-55,940 was discovered in 1974 and is one of the most studied member of this class.

The description in these text boxes highlight only the properties associated with CP-55,940

Other Names:

CP Family of Synthetic Cannabinoids
CP55,940; CP-55,940; CP-55940 plus numerous supplier-based synonyms.

IUPAC Name: 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol

Molecular Formula: C24H40O3

CP-x Synthetic Cannabinoids Properties and Effects

CP-55,940 may induce:
• Apoptosis in human embryonic rhabdomyosarcoma cell line (Ken-Ichi Tomiyama et al., 2020).
• Apoptosis in glioblastoma cell lines i.e., C6 and U373 (A. Ortega et al., 2015).
• Analgesic effects following hypoxia reoxygenation with potential relevance to severe pain in sickle cell disease (David Cain et al., 2013).
• Reduction of SKF (dopamine D1 receptor agonist)-induced oral dyskinesia (Morten V Madsen et al., 2011).

CP-x Synthetic Cannabinoids Receptor Binding

Endocannabinoid System (ECS) and CP-55,940:
• CB1 a mean Kd at 2.5nM (10 times more potent than THC).
• CB2 a mean Kd at 0.92nM (38 times more potent than THC).

Endocannabinoidome (eCBome) and CP-55,940:
• PPAR-Gamma (initiates anti-inflammatory response)
• GPR55

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.